File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Conference Paper: The thromboxane/endoperoxide receptor (TP): The common villain

TitleThe thromboxane/endoperoxide receptor (TP): The common villain
Authors
Issue Date2010
PublisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/
Citation
Annual Scientific Meeting of the Institute-of-Cardiovascular-Science-and-Medicine, Hong Kong, Peoples of China, 13 December, 2009. In Journal Of Cardiovascular Pharmacology, 2010, v. 55 n. 4, p. 317-332 How to Cite?
AbstractThe stimulation of thromboxane/endoperoxide receptors (TP) elicits diverse physiological/pathophysiological reactions, including platelet aggregation and contraction of vascular smooth muscle. Furthermore, the activation of endothelial TP promotes the expression of adhesion molecules and favors adhesion and infiltration of monocytes/macrophages. In various cardiovascular diseases, endothelial dysfunction is predominantly the result of the release of endothelium-derived contracting factors that counteract the vasodilator effect of nitric oxide produced by the endothelial nitric oxide synthase. Endothelium-dependent contractions involve the activation of cyclooxygenases, the production of reactive oxygen species along with that of endothelium-derived contracting factors, which diffuse toward the vascular smooth muscle cells and activate their TP. TP antagonists curtail the endothelial dysfunction in diseases such as hypertension and diabetes, are potent antithrombotic agents, and reduce vascular inflammation. Therefore, TP antagonists, because of this triple activity, may have a unique potential for the treatment of cardiovascular disorders. © 2010 by Lippincott Williams & Wilkins.
Persistent Identifierhttp://hdl.handle.net/10722/173547
ISSN
2015 Impact Factor: 2.462
2015 SCImago Journal Rankings: 0.962
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorFeletou, Men_US
dc.contributor.authorVanhoutte, PMen_US
dc.contributor.authorVerbeuren, TJen_US
dc.date.accessioned2012-10-30T06:32:37Z-
dc.date.available2012-10-30T06:32:37Z-
dc.date.issued2010en_US
dc.identifier.citationAnnual Scientific Meeting of the Institute-of-Cardiovascular-Science-and-Medicine, Hong Kong, Peoples of China, 13 December, 2009. In Journal Of Cardiovascular Pharmacology, 2010, v. 55 n. 4, p. 317-332en_US
dc.identifier.issn0160-2446en_US
dc.identifier.urihttp://hdl.handle.net/10722/173547-
dc.description.abstractThe stimulation of thromboxane/endoperoxide receptors (TP) elicits diverse physiological/pathophysiological reactions, including platelet aggregation and contraction of vascular smooth muscle. Furthermore, the activation of endothelial TP promotes the expression of adhesion molecules and favors adhesion and infiltration of monocytes/macrophages. In various cardiovascular diseases, endothelial dysfunction is predominantly the result of the release of endothelium-derived contracting factors that counteract the vasodilator effect of nitric oxide produced by the endothelial nitric oxide synthase. Endothelium-dependent contractions involve the activation of cyclooxygenases, the production of reactive oxygen species along with that of endothelium-derived contracting factors, which diffuse toward the vascular smooth muscle cells and activate their TP. TP antagonists curtail the endothelial dysfunction in diseases such as hypertension and diabetes, are potent antithrombotic agents, and reduce vascular inflammation. Therefore, TP antagonists, because of this triple activity, may have a unique potential for the treatment of cardiovascular disorders. © 2010 by Lippincott Williams & Wilkins.en_US
dc.languageengen_US
dc.publisherLippincott Williams & Wilkins. The Journal's web site is located at http://www.cardiovascularpharm.com/en_US
dc.relation.ispartofJournal of Cardiovascular Pharmacologyen_US
dc.subject.meshAnimalsen_US
dc.subject.meshCardiovascular Diseases - Drug Therapy - Metabolism - Physiopathologyen_US
dc.subject.meshEndothelium, Vascular - Metabolism - Physiopathologyen_US
dc.subject.meshHumansen_US
dc.subject.meshMuscle, Smooth, Vascular - Metabolism - Physiopathologyen_US
dc.subject.meshReceptors, Thromboxane A2, Prostaglandin H2 - Antagonists & Inhibitors - Metabolismen_US
dc.titleThe thromboxane/endoperoxide receptor (TP): The common villainen_US
dc.typeConference_Paperen_US
dc.identifier.emailVanhoutte, PM:vanhoutt@hku.hken_US
dc.identifier.authorityVanhoutte, PM=rp00238en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1097/FJC.0b013e3181d8bc8aen_US
dc.identifier.pmid20422736-
dc.identifier.scopuseid_2-s2.0-77951712638en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-77951712638&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume55en_US
dc.identifier.issue4en_US
dc.identifier.spage317en_US
dc.identifier.epage332en_US
dc.identifier.isiWOS:000277307900004-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridFeletou, M=7006461826en_US
dc.identifier.scopusauthoridVanhoutte, PM=7202304247en_US
dc.identifier.scopusauthoridVerbeuren, TJ=7007006534en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats